Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-14 | estimated | When the study began enrolling |
| Primary completion | 2026-06-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-06 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-07-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cutaneous Squamous Cell Carcinoma
Interventions
- Drug: cemiplimab — also filed as REGN2810, Libtayo
- Drug: fianlimab — also filed as REGN3767
Primary outcome
what the primary-completion date above is the date OFPathological complete response (pCR) rate by blinded independent pathological review (BIPR)
measured Up to 100 days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed